|
|
News Breaks
|
February 1, 2010
|
| 11:00 EDT |  | ABT |
| theflyonthewall.com: | Abbott Lab announces collaboration with Pierre Fabre SA for h224G11 | | Abbott announced an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre in France and targeting the cMet receptor for the treatment of cancer. cMet protein plays a role in the progression of a range of solid tumors including, prostate, lung and gastric cancers and mediates resistance to chemotherapy. As part of the agreement, the companies also intend to collaborate on research to explore next-generation cMet antibodies. Under the terms of the collaboration and license agreement, Abbott will lead the development and commercialization of monoclonal antibodies targeting the cMet receptor. Pierre Fabre SA will receive an initial $25M upfront payment and research funding to support further discovery efforts for two years. Additional terms of the agreement, including milestones and royalty payments, remain confidential. :theflyonthewall.com |
|
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 7, 2012
|
| 10:33 EDT |  | ABT |
| theflyonthewall.com: | Argus Research's healthcare analyst holds a conference call | | Senior Healthcare Analyst Toung discusses healthcare and growth ideas for 2012 on an Analyst/Industry conference call. Relevant covered companies ABC, ABT, AET, BAX, BDX, BSX, CAH, CHSI, CI, ESRX, HMA, HOLX, HUM, IART, JNJ, MCK, MDT, MHS, STJ, SYK, UNH and ZMH may be included on the Analyst/Industry conference call to be held on February 8 at 11 am. :theflyonthewall.com |
|
|
January 30, 2012
|
| 06:07 EDT | | ABT |
| theflyonthewall.com: | Abbott, DNDi in partnership to boost innovation for neglected tropical diseases | | The Drugs for Neglected Diseases initiative, or DNDi, and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases. :theflyonthewall.com |
|
|
|
|
|
